Poxel to Host Conference Call for Full Year 2019 Financial Results and Provide Corporate Update on March 26, 2020 at 2:30 pm ...
23 Mars 2020 - 5:45PM
Business Wire
POXEL S.A. (Euronext – POXEL - FR0012432516), a
biopharmaceutical company focused on the development of innovative
treatments for metabolic disorders, including type 2 diabetes and
non-alcoholic steatohepatitis (NASH), today announced that it will
report and present its financial results for the full year 2019 and
provide a corporate update on Thursday, March 26, 2020.
The management team will host a conference call on March 26,
2020, in English, at 2:30 pm EDT (New York time) / 7:30 pm CET
(Paris time) to discuss the financial results and
provide a corporate update.
Please note that the time for this call has been updated from
the press release issued on March 4, 2020.
The press release announcing Poxel’s financial results for
full year 2019 and corporate update will be issued after the
Euronext Paris market closes. A presentation will be available
in the Investors section of the Poxel website:
https://www.poxelpharma.com/en_us/investors
To access the conference call, please use the dial-in numbers
below according to your location.
US: +1 (646) 722 4916 UK: +44 (0) 20 7194 3759 FR: +33 (0) 1 72
72 74 03 Access code: 53593329#
Following the live call, a replay will be available for 90 days.
To access the replay, please use one of the following numbers.
US: +1 (646) 722 4969 UK: +44 (0) 20 3364 5147 FR: +33 (0) 1 70
71 01 60 Access code: 418906110#
About Poxel SA Poxel is a dynamic biopharmaceutical
company that uses its extensive expertise in developing
innovative drugs for metabolic diseases, with a focus on
type 2 diabetes and non-alcoholic steatohepatitis
(NASH). In its mid-to-late stage pipeline, the Company is
currently advancing three drug candidates as well as earlier-stage
opportunities. Imeglimin, Poxel’s first-in-class lead
product, targets mitochondrial dysfunction. Together, with its
partner Sumitomo Dainippon Pharma, Poxel successfully completed the
Phase 3 Trials of IMeglimin for Efficacy and
Safety (TIMES) program for the treatment of type 2 diabetes
in Japan. Poxel also established a partnership with Roivant
Sciences for Imeglimin’s development and commercialization in
countries outside of the partnership with Sumitomo Dainippon
Pharma, including the U.S. and Europe. PXL770, a
first-in-class direct adenosine monophosphate-activated protein
kinase (AMPK) activator, is in a Phase 2a proof-of-concept program
for the treatment of NASH. PXL770 could also have the potential to
treat additional metabolic diseases. PXL065
(deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate
carrier (MPC) inhibitor, is advancing into a Phase 2 clinical trial
for the treatment of NASH. Poxel also has additional earlier-stage
programs targeting metabolic, specialty and rare diseases. The
Company intends to generate further growth through strategic
partnerships and pipeline development. Listed on Euronext Paris,
Poxel is headquartered in Lyon, France, and has subsidiaries in
Boston, MA, and Tokyo, Japan. For more information, please visit:
www.poxelpharma.com.
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200323005477/en/
Poxel SA Jonae R. Barnes Senior Vice President, Investor
Relations and Public Relations jonae.barnes@poxelpharma.com +1 617
818 2985 Aurélie Bozza Investor Relations and Communication
Director aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
Investor relations / Media - EU/US Trophic Communications
Joanne Tudorica or Valeria Fisher tudorica@trophic.eu or
fisher@trophic.eu +49 171 351 2733 or +49 175 804 1816 Investor
relations / Media - France NewCap Alexia Faure or Arthur
Rouillé poxel@newcap.eu +33 1 44 71 94 94
Poxel (EU:POXEL)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Poxel (EU:POXEL)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024